Antisoma Takes Refuge With Roche

Roche could easily have swallowed cash-poor Antisoma whole. But the Swiss group has instead bought rights to the UK biotech's entire clinical portfolio, hoping thereby to preserve Antisoma's creativity--rather like it has done with Genentech.

At least one of the UK's biotech companies is home and dry. Much of the sector is paying a high price for failing to raise enough cash during the biotech boom, and remains stubbornly resistant to consolidation. (See "UK Biotech Learns the Hard Way," START-UP, March 2002 Also see "UK Biotech Learns the Hard Way" - Scrip, 1 March, 2002..)

Cancer company Antisoma PLC was no exception. To avoid dilution, it only raised top-up funding of £8.7 million ($13.7...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo